Compare PCRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ATRO |
|---|---|---|
| Founded | 2006 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.9M | 3.5B |
| IPO Year | 2010 | 1995 |
| Metric | PCRX | ATRO |
|---|---|---|
| Price | $25.87 | $76.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $30.25 | ★ $86.00 |
| AVG Volume (30 Days) | 434.1K | ★ 636.6K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 276.09 |
| EPS | 0.19 | ★ 1.31 |
| Revenue | $541,533,000.00 | ★ $862,128,000.00 |
| Revenue This Year | $6.78 | $14.92 |
| Revenue Next Year | $8.54 | $8.81 |
| P/E Ratio | $138.68 | ★ $58.21 |
| Revenue Growth | ★ 26.04 | 8.39 |
| 52 Week Low | $18.80 | $39.14 |
| 52 Week High | $27.66 | $99.89 |
| Indicator | PCRX | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 49.10 |
| Support Level | $21.97 | $71.01 |
| Resistance Level | $26.94 | $81.60 |
| Average True Range (ATR) | 0.64 | 3.24 |
| MACD | 0.16 | -0.59 |
| Stochastic Oscillator | 69.54 | 28.26 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.